ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
- Conditions
- Chronic Hepatitis CHepatitis C VirusHCVDirect-Acting Antiviral Agent (DAA)-Experienced
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 141
- Registration Number
- NCT02446717
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 222
- Registration Number
- NCT02442271
Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 46
- Registration Number
- NCT02442258
- Locations
- 🇺🇸
Site Reference ID/Investigator# 132890, Miami, Florida, United States
🇳🇿Site Reference ID/Investigator# 137332, Grafton, Auckland, New Zealand
🇺🇸Site Reference ID/Investigator# 132889, Orlando, Florida, United States
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 214
- Registration Number
- NCT02443298
- Locations
- 🇬🇧
Wishaw General Hospital, Wishaw, United Kingdom
🇳🇱HagaZiekenhuis, Den Haag, Netherlands
🇵🇱Univ. Hospital in Krakow,Pulmonology Clinical Dept, Krakow, Poland
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
- Conditions
- Hepatitis C VirusChronic Hepatitis CCirrhosis
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 99
- Registration Number
- NCT02442284
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 384
- Registration Number
- NCT02441283
- Locations
- 🇨🇦
Toronto Liver Centre /ID# 155401, Toronto, Ontario, Canada
🇺🇸Digestive Health Specialists of the Southeast /ID# 136725, Dothan, Alabama, United States
🇺🇸Southern California Res. Ctr. /ID# 141799, Coronado, California, United States
Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 158
- Registration Number
- NCT02433340
A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 168
- Registration Number
- NCT02429895
- Locations
- 🇧🇬
Site Reference ID/Investigator# 138926, Plovdiv, Bulgaria
🇵🇱Site Reference ID/Investigator# 139000, Bialystok, Poland
🇧🇬Site Reference ID/Investigator# 138928, Sofia, Bulgaria
Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])
- Conditions
- Psoriatic Arthritis
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 148
- Registration Number
- NCT02414633
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer Stage III
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT02412371
- Locations
- 🇺🇸
Rhode Island Hospital /ID# 133493, Providence, Rhode Island, United States
🇺🇸Univ Maryland School Medicine /ID# 132944, Baltimore, Maryland, United States
🇺🇸Dana-Farber Cancer Institute /ID# 133494, Boston, Massachusetts, United States